Sichenzia Ross Ference LLP Represents Novume Solutions, Inc. in $3.3 Million Underwritten Public Offering of Common Stock
Press Release – New York, NY – November 1, 2018 – Sichenzia Ross Ference LLP announced today that it has represented Novume Solutions, Inc. (NASDAQ “NVMM”) in a public offering of 4.125 million shares of its common stock at a price of $.80 per share for gross proceeds to the Company of $3.3 million.
Think Equity, a Division of Fordham Financial Management, and The Benchmark Group acted as co-book running managers for the offering. The Sichenzia Ross Ference team was led by Partners Gregory Sichenzia, Thomas Rose, and Marcelle S. Balcombe.
.jpg)
Sichenzia Ross Ference LLP
Sichenzia Ross Ference LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Super Lawyers consistently recognizes our attorneys as among the highest rated securities lawyers in the nation. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on major capital stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals. We also represent clients in a range of residential and commercial real estate and trusts and estates matters.
Visit SRF's LinkedIn page
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents A.G.P/ Alliance Global Partners in $3.5 Million Public Offering for Safe-T Group Ltd. - November 6, 2019
- Sichenzia Ross Ference LLP Represents Document Security Systems, Inc. in a $1.8 Million Private Placement - November 5, 2019
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $3 Million Public Offering of Common Stock of Cocrystal Pharma, Inc. - November 4, 2019
